Takeda Pharmaceutical Company(GB:0A87)
$21.66+0.32 (+1.50%)
GB:0A87
Takeda Pharmaceutical Company financials statements
$21.66
At close:+0.32 (+1.50%)
Takeda Pharmaceutical Company (0A87) Income Statement
3 Followers
Takeda Pharmaceutical Company Income Statement
Last quarter (Q2 2026), Takeda Pharmaceutical Company's total revenue was ¥1.19T, an increase of 6.68% from the same quarter last year. In Q2, Takeda Pharmaceutical Company's net income was ¥192.43B. See Takeda Pharmaceutical Company’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Mar 26 | Mar 25 | Mar 24 | Mar 23 | Mar 22 |
|---|---|---|---|---|---|
| ¥ 4.78T | ¥ 4.58T | ¥ 4.26T | ¥ 4.03T | ¥ 3.57T | |
| ¥ 2.44T | ¥ 3.00T | ¥ 2.83T | ¥ 2.78T | ¥ 2.46T | |
| ¥ 1.87T | ¥ 2.66T | ¥ 2.62T | ¥ 2.29T | ¥ 2.00T | |
| Depreciation and Amortization | ¥ 721.13B | ¥ 761.40B | ¥ 728.00B | ¥ 664.40B | ¥ 583.15B |
| ¥ 1.38T | ¥ 1.21T | ¥ 1.23T | ¥ 1.28T | ¥ 1.18T | |
| ¥ 573.04B | ¥ 342.59B | ¥ 214.07B | ¥ 490.50B | ¥ 460.84B | |
| ¥ -297.16B | ¥ -167.50B | ¥ -161.28B | ¥ -115.42B | ¥ -158.27B | |
| ¥ 275.88B | ¥ 175.08B | ¥ 52.79B | ¥ 375.09B | ¥ 302.57B | |
| ¥ 203.33B | ¥ 107.93B | ¥ 144.07B | ¥ 317.02B | ¥ 230.06B | |
| Per Share Metrics | |||||
| Basic EPS | ¥ 63.91 | ¥ 34.17 | ¥ 46.05 | ¥ 102.15 | ¥ 73.57 |
| Diluted EPS | ¥ 63.91 | ¥ 33.62 | ¥ 45.58 | ¥ 100.97 | ¥ 72.94 |
| Weighted Average Shares Outstanding | 3.15B | 3.21B | 3.13B | 3.10B | 3.13B |
| Weighted Average Shares Outstanding (Diluted) | 3.21B | 3.21B | 3.16B | 3.14B | 3.15B |
Currency in JPY
